Literature DB >> 19124532

Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models.

Jack Phan1, Miriam A Hickey, Peixiang Zhang, Marie-Francoise Chesselet, Karen Reue.   

Abstract

In addition to the hallmark neurological manifestations of Huntington's disease (HD), weight loss with metabolic dysfunction is often observed in the later stages of disease progression and is associated with poor prognosis. The mechanism for weight loss in HD is unknown. Using two mouse models of HD, the R6/2 transgenic and CAG140 knock-in mouse strains, we demonstrate that adipose tissue dysfunction is detectable at early ages and becomes more pronounced as the disease progresses. Adipocytes acquire a 'de-differentiated' phenotype characterized by impaired expression of fat storage genes. In addition, HD mice exhibit reduced levels of leptin and adiponectin, adipose tissue-derived hormones that regulate food intake and glucose metabolism. Importantly, some of these changes occur prior to weight loss and development of some of the characteristic neurological symptoms. We demonstrate that impaired gene expression and lipid accumulation in adipocytes can be recapitulated by expression of an inducible mutant huntingtin transgene in an adipocyte cell line and that mutant huntingtin inhibits transcriptional activity of the PGC-1alpha co-activator in adipocytes, which may contribute to aberrant gene expression. Thus, our findings indicate that mutant huntingtin has direct detrimental effects in cell types other than neurons. The results also indicate that circulating adipose-tissue-derived hormones may be accessible markers for HD prognosis and progression and suggest that adipose tissue may be a useful therapeutic target to improve standard of life for HD patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124532      PMCID: PMC2649017          DOI: 10.1093/hmg/ddn428

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  63 in total

Review 1.  Metabolic control through the PGC-1 family of transcription coactivators.

Authors:  Jiandie Lin; Christoph Handschin; Bruce M Spiegelman
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

Review 2.  Metabolic consequences of lipodystrophy in mouse models.

Authors:  Karen Reue; Jack Phan
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-07       Impact factor: 4.294

3.  Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.

Authors:  K Josefsen; M D Nielsen; K H Jørgensen; T Bock; A Nørremølle; S A Sørensen; B Naver; L Hasholt
Journal:  J Neuroendocrinol       Date:  2007-11-22       Impact factor: 3.627

4.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

5.  Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

Authors:  Julie St-Pierre; Stavit Drori; Marc Uldry; Jessica M Silvaggi; James Rhee; Sibylle Jäger; Christoph Handschin; Kangni Zheng; Jiandie Lin; Wenli Yang; David K Simon; Robert Bachoo; Bruce M Spiegelman
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

6.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.

Authors:  Patrick Weydt; Victor V Pineda; Anne E Torrence; Randell T Libby; Terrence F Satterfield; Eduardo R Lazarowski; Merle L Gilbert; Gregory J Morton; Theodor K Bammler; Andrew D Strand; Libin Cui; Richard P Beyer; Courtney N Easley; Annette C Smith; Dimitri Krainc; Serge Luquet; Ian R Sweet; Michael W Schwartz; Albert R La Spada
Journal:  Cell Metab       Date:  2006-10-19       Impact factor: 27.287

7.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease.

Authors:  R Luthi-Carter; A Strand; N L Peters; S M Solano; Z R Hollingsworth; A S Menon; A S Frey; B S Spektor; E B Penney; G Schilling; C A Ross; D R Borchelt; S J Tapscott; A B Young; J H Cha; J M Olson
Journal:  Hum Mol Genet       Date:  2000-05-22       Impact factor: 6.150

8.  Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

Authors:  Elizabeth A McCaw; Haibei Hu; Geraldine T Gomez; Andrea L O Hebb; Melanie E M Kelly; Eileen M Denovan-Wright
Journal:  Eur J Biochem       Date:  2004-12

9.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

Authors:  Richard R Ribchester; Derek Thomson; Nigel I Wood; Tim Hinks; Thomas H Gillingwater; Thomas M Wishart; Felipe A Court; A Jennifer Morton
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

Review 10.  Obesity and lipodystrophy--where do the circles intersect?

Authors:  Farid F Chehab
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

View more
  42 in total

1.  Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease.

Authors:  Miriam A Hickey; Chunni Zhu; Vera Medvedeva; Nicholas R Franich; Michael S Levine; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2011-10-20       Impact factor: 4.314

Review 2.  Huntington's disease: progress toward effective disease-modifying treatments and a cure.

Authors:  Carl D Johnson; Beverly L Davidson
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 3.  Polyglutamine toxicity in non-neuronal cells.

Authors:  Jennifer W Bradford; Shihua Li; Xiao-Jiang Li
Journal:  Cell Res       Date:  2010-03-16       Impact factor: 25.617

4.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

5.  Long Term Aggresome Accumulation Leads to DNA Damage, p53-dependent Cell Cycle Arrest, and Steric Interference in Mitosis.

Authors:  Meng Lu; Chiara Boschetti; Alan Tunnacliffe
Journal:  J Biol Chem       Date:  2015-09-25       Impact factor: 5.157

Review 6.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

7.  Fat-free mass and its predictors in Huntington's disease.

Authors:  S D Süssmuth; V M Müller; C Geitner; G B Landwehrmeyer; S Iff; A Gemperli; Michael Orth
Journal:  J Neurol       Date:  2015-04-23       Impact factor: 4.849

8.  Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.

Authors:  Robert B Laprairie; Amina M Bagher; Jillian L Rourke; Adel Zrein; Elizabeth A Cairns; Melanie E M Kelly; Christopher J Sinal; Pushkar M Kulkarni; Ganesh A Thakur; Eileen M Denovan-Wright
Journal:  Neuropharmacology       Date:  2019-03-30       Impact factor: 5.250

Review 9.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.